Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.56 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19981610 | 1.00 | OPRM1 (0.56) | OPRM1OPRD1OPRK1PSMB5CTSB | |
| SCHEMBL26947402 | 0.98 | OPRM1 (0.55) | OPRM1OPRD1OPRK1PSMB5CTSB | |
| SCHEMBL22520845 | 0.95 | CTSB (0.55) | OPRM1OPRD1OPRK1PSMB5CTSB | |
| SCHEMBL22520851 | 0.94 | OPRM1 (0.59) | OPRM1OPRD1OPRK1PSMB5CTSB | |
| SCHEMBL24451386 | 0.92 | OPRM1 (0.50) | OPRM1OPRD1OPRK1PSMB5CTSB | |
| SCHEMBL22105953 | 0.92 | OPRM1 (0.55) | OPRM1OPRD1OPRK1CTSBKEAP1 | |
| SCHEMBL25467504 | 0.92 | PSMB5 (0.54) | OPRM1OPRD1OPRK1PSMB5CTSB | |
| SCHEMBL22106073 | 0.91 | OPRM1 (0.55) | OPRM1OPRD1OPRK1CTSBKEAP1 | |
| SCHEMBL22106071 | 0.90 | OPRM1 (0.54) | OPRM1OPRD1OPRK1CTSBKEAP1 | |
| SCHEMBL22105888 | 0.90 | OPRM1 (0.53) | OPRM1OPRD1OPRK1CTSBKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200069767-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069767-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | MAVS, MYD88, CD47 | OPRM1 4668/4885OPRD1 4699/4885OPRK1 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.